All Stories

  1. Digital Health and Self-Management in Idiopathic Inflammatory Myopathies: A Missed Opportunity?
  2. POS0537 GLOBAL PERSPECTIVES ON GLUCOCORTICOID MANAGEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THE LUPHPOS SURVEY
  3. AB1490 JAK INHIBITORS AND INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC AUTOIMMUNE DISEASES (SADS-ILD): A SYSTEMATIC REVIEW OF THE LITERATURE
  4. Cardiovascular disease in patients with systemic autoimmune diseases: The relationship between self-perceived risk and actual risk
  5. KL6 and IL-18 levels are negatively correlated with respiratory function tests and ILD extent assessed on HRCT in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD)
  6. P151 Nailfold capillaroscopy for prediction of novel severe organ involvement and mortality in systemic sclerosis
  7. Breakthrough SARS-CoV-2 infection and disease flares in patients with rheumatoid arthritis: result from COVAD e-survey study
  8. P30 Polyautoimmunity phenomenon in systemic lupus erythematosus (SLE): secondary sjogren syndrome (sSS)
  9. O3 Physician experience influences glucocorticoid prescribing patterns in systemic lupus erythematosus (SLE): results from the LUPHPOS survey
  10. Risk factors for cardiovascular disease in primary Sjögren’s syndrome (pSS): a 20-year follow-up study
  11. AB0862 NAILFOLD CAPILLAROSCOPY FOR PREDICTION OF NOVEL SEVERE ORGAN INVOLVEMENT IN SYSTEMIC SCLEROSIS
  12. P147 Predictors of interstitial lung involvement in systemic sclerosis
  13. Clinical phenotype in scleroderma patients based on autoantibodies
  14. Atypical Debut of Granulomatosis with Polyangiitis as Acute Tonsilitis and Strawberry Gum: A Case Report
  15. Factors Associated With Adverse Outcomes in Uveitis Related to Spondyloarthritis
  16. Serological and/or Immunological Biomarkers Influence the Clinical Phenotype of Extraglandular Manifestations in Primary Sjögren's Syndrome
  17. PO.8.179 Factors associated with adverse pregnancy outcomes in patients with systemic lupus erythematosus
  18. Cancer in systemic sclerosis: association between antibodies and malignancy
  19. Factors associated with adverse pregnancy outcomes in patients with systemic lupus erythematosus
  20. AB0451 FACTORS ASSOCIATED WITH ADVERSE PREGNANCY OUTCOMES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
  21. AB0647 Clinical phenotype in scleroderma patients with limited and diffuse cutaneous disease based on autoimmunity
  22. AB0648 Cancer in systemic sclerosis: association between antibodies and malignancy and results from a third-level center
  23. AB0706 Demographic, clinical and serological characteristics in Idiopathic Inflammatory Myopathies. The role of specific antibodies
  24. AB0797 Factors associated with Adverse Outcomes in Uveitis related to Spondylarthritis (SpA-U)- Development of a Prognostic Outcome Score in Patients with SpA-U
  25. POS0843 PREDICTORS OF INTERSTITIAL LUNG INVOLVEMENT AND TIMING OF ONSET IN SYSTEMIC SCLEROSIS: OUR EXPERIENCE AT A THIRD-LEVEL HOSPITAL
  26. POS1191 IMMUNE RESPONSES TO MRNA VACCINES AGAINST SARS-COV2 IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES
  27. Antiphospholipid Antibodies in Patients with COVID-19
  28. Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases
  29. Refractory Behçet’s Disease with Multi-organ Involvement - Learning from Failure
  30. Polyautoimmunity in systemic lupus erythematosus: secondary Sjogren syndrome
  31. AB0278 OFF-LABEL RITUXIMAB FOR SYSTEMIC AUTOIMMUNE DISEASES: A CASE SERIES FROM A THIRD LEVEL HOSPITAL DURING A 5 YEAR- PERIOD
  32. AB0290 TREATMENT OF INTERSTITIAL LUNG INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS: EXPERIENCE IN A THIRD LEVEL HOSPITAL
  33. AB0568 CORRELATION BETWEEN SKIN AND JOINT INVOLVEMENT IN PATIENTS WITH PSORIATIC ARTHRITIS: EXPERIENCE FROM A THIRD LEVEL HOSPITAL
  34. Anti-TNF-α-induced lupus syndrome
  35. Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
  36. Post-coronavirus disease syndrome and disseminated microthrombosis: the role of the von Willebrand factor and antiphospholipid antibodies
  37. Biologic agents for rheumatic diseases in the break of COVID-19: friend or foe?
  38. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease
  39. Antiphospholipid antibodies in patient with acute lower member ischemia and pulmonary thromboembolism as a result of infection by SARS-CoV2